Reimagining Medicine slide image

Reimagining Medicine

Company overview Financial review 2023 priorities Appendix Novartis proposes 26th consecutive dividend increase to the AGM: 3.20 CHF / share¹ 2022 Dividend yield 3.8%² Dividend growth 3.2%3 CHF dividend USD dividend4 3.5 3.0 2.5 2.0 1996-2022 CAGR CHF: 7.4% USD: 9.3%4 1.5 1.0 0.5 0.0 T FINANCIAL PROFILE 2022 proposal: CHF 3.20 USD 3.464 2021: CHF 3.10 USD 3.334 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 1. Proposal to shareholders at the 2023 Annual General Meeting, taking place on March 7, 2023 2. Based on closing share price of CHF 83.59 at end of business year 2022 (December 30, 2022) 3. In CHF 4. Historical dividends per share converted at historical exchange rates at the dividend payment dates as per Bloomberg; for 2022, translated into US dollars at the FX rate of CHF/USD of 1.081, as of December 31, 2022 38 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine
View entire presentation